Our mission
is to build a healthier tomorrow for people with progressive non-viral liver diseases
Intercept Today: Established Expertise in Liver Disease
Sustainable and growing PBC
business with Ocaliva
Strong revenue of ~$343M
non-GAAP adjusted net sales
(~$285M U.S. net sales), representing ~10% growth in FY 2022*
OCA+bezafibrate fixed- dose combination Phase
2 development program ongoing
Progressing OCA for
pre-cirrhotic liver fibrosis
due to NASH
NDA re-submitted in December 2022
NDA supported by robust NASH development program, including two positive interim analyses from the Phase 3 REGENERATE study
Advancing internal pipeline in liver diseases with high unmet need
Initiated Phase 2a FRESH study with INT-787 in severe alcohol- associated hepatitis
Evaluating and prioritizing short- and long-term internal and external opportunities aligned with our core strengths
Fully integrated organization with ~350 employees focused exclusively in liver disease
Strengthened financial position and an overall improved capital structure
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.